Karyopharm Reports FDA Panel To Review Selinexor For Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies On Feb. 26, 2019 At 12:30 p.m. EST
Benzinga Newsdesk